MacroGenics, Inc. (NASDAQ:MGNX) Shares Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP grew its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 117.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 207,877 shares of the biopharmaceutical company’s stock after purchasing an additional 112,188 shares during the period. GSA Capital Partners LLP owned 0.33% of MacroGenics worth $684,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of MGNX. ProShare Advisors LLC raised its stake in MacroGenics by 8.9% during the first quarter. ProShare Advisors LLC now owns 15,282 shares of the biopharmaceutical company’s stock worth $225,000 after acquiring an additional 1,246 shares during the period. EntryPoint Capital LLC acquired a new stake in shares of MacroGenics during the 1st quarter worth approximately $40,000. CANADA LIFE ASSURANCE Co bought a new stake in shares of MacroGenics in the 1st quarter worth approximately $52,000. Principal Financial Group Inc. boosted its position in MacroGenics by 1.1% during the 2nd quarter. Principal Financial Group Inc. now owns 348,421 shares of the biopharmaceutical company’s stock valued at $1,481,000 after purchasing an additional 3,818 shares during the period. Finally, Diversified Trust Co grew its stake in MacroGenics by 32.8% during the 2nd quarter. Diversified Trust Co now owns 18,097 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 4,467 shares during the last quarter. 96.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on MGNX. BMO Capital Markets cut their target price on MacroGenics from $8.00 to $5.00 and set a “market perform” rating on the stock in a research note on Wednesday, August 7th. Evercore ISI upgraded shares of MacroGenics to a “strong-buy” rating in a research report on Monday, September 16th. HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price target on shares of MacroGenics in a report on Wednesday, November 6th. Guggenheim downgraded MacroGenics from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 31st. Finally, Barclays lowered their target price on MacroGenics from $14.00 to $9.00 and set an “overweight” rating on the stock in a research report on Monday, July 29th. Eight analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $7.63.

MacroGenics Price Performance

Shares of MGNX opened at $3.57 on Monday. The firm’s 50 day moving average is $3.67 and its 200-day moving average is $4.50. MacroGenics, Inc. has a 12-month low of $2.95 and a 12-month high of $21.88. The stock has a market capitalization of $224.05 million, a P/E ratio of -2.26 and a beta of 2.08.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.